Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on February 18, 2020. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "COCP". The report primarily serves to disclose a scheduled investor presentation.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate event rather than a financial statement.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document announces a scheduled presentation by the Chief Executive Officer at the Noble Capital Markets' 16th Annual Investor Conference.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the presentation. The filing explicitly states that the information contained in Item 7.01 and the accompanying presentation (Exhibit 99.1) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities under such section. Consequently, no formal guidance or risk factors are detailed within the body of this specific 8-K report.
Key Facts for Investor Verification
- Verify the content of the corporate presentation (Exhibit 99.1) for any forward-looking statements or strategic updates, noting that this exhibit is not legally "filed" under the Exchange Act.
- Confirm the date and time of the CEO's presentation: February 18, 2020, at 11:30 a.m. ET.
- Review subsequent filings (such as 10-K or 10-Q) for actual financial performance data, as this 8-K contains no financial metrics.